Project Grant R43TR006331
Award Date 7/15/26
Completion Date 7/14/27
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48108, USA
Similar Awards
- Federal Grant Award Summary Intero Biosystems Inc. received a $349,952 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 20, 2025, with a completion date of June 19, 2026. In collaboration with the University of Michigan, the awardee is developing and validating a novel stem cell-derived human intestinal organoid (HIO) screening platform designed to improve preclinical drug testing and reduce the current 90% failure rate of drug...
- Federal Grant Award Summary Award Details: Intero Biosystems Inc. received a $1,046,897 Project Grant from the National Center for Advancing Translational Sciences (NCATS), NIH (CFDA 93.350) effective July 1, 2026, through June 30, 2028, to develop and commercialize a novel human intestinal organoid (HIO) screening platform for pharmaceutical drug discovery and preclinical testing. Products and Services: Under this Phase II award, Intero Biosystems will scale production methods and establish...
- Federal Grant Award Summary Piccolo Biosystems, Inc. received a $295,861 Phase I Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2026. In collaboration with the University of Washington, Piccolo will develop and validate an innovative ultra-small scale assay platform for measuring enzyme inhibition, specifically...
- Federal Grant Award Summary Foli Bio Inc. received a $305,000 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a high-throughput fecal exfoliome analyzing platform for clinical drug development. The award, initiated October 1, 2025, with completion targeted for September 30, 2026, funds the advancement of a stool-based diagnostic technology that captures and...
- Federal Grant Award Summary Biotherapeutics, Inc. received a $628,726 SBIR Phase 1 Project Grant awarded on August 13, 2025, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports the development of a novel, host-targeted, antibiotic-sparing oral therapeutic for the concurrent treatment of Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD). The innovative...
- Federal Project Grant Award Summary Integrated Micro-Chromatography Systems, Inc. (IMCS) received a $315,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period September 1, 2025 through August 31, 2026. The award supports the development of chemoenzymatic methods and production of glycosphingolipids (GSLs), which are complex carbohydrate-containing lipids found on cell membranes...
- Federal Project Grant Award Summary Caleo Biotechnologies, Inc. received a $289,435 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) to develop patient-derived, multicellular tissue models for studying colitis-associated colorectal cancer. The project, awarded July 1, 2026 with completion targeted for June 30, 2027, will generate self-assembling tissue systems that integrate...
- Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) on July 1, 2026, to develop a novel precision microbiome-based therapeutic platform for phenylketonuria (PKU). The company is engineering native bacterial strains designed to deliver persistent functional activity within the proximal gut, addressing...
- Federal Project Grant Award Summary Objective Biotechnology, Inc., a Minneapolis-based minority-owned biotechnology firm, received a $416,925 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) on September 15, 2025, with an ultimate completion date of August 31, 2027. The grant supports the development and commercialization of the mini-mscope, a miniaturized imaging device designed for mesoscale...
- Federal Project Grant Award Summary Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) received a $306,872 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period August 1, 2025 through July 31, 2026. The award supports development of a commercial prototype for an ultrahigh-throughput biocatalyst evolution platform that combines precision nanoliter fluid handling, label-free...